Journal
CHEMICAL RESEARCH IN TOXICOLOGY
Volume 17, Issue 8, Pages 999-1006Publisher
AMER CHEMICAL SOC
DOI: 10.1021/tx049904e
Keywords
-
Ask authors/readers for more resources
Clinical chelation therapy of mercury poisoning generally uses one or both of two drugs-meso-dimercaptosuccinic acid (DMSA) and dimercaptopropanesulfonic acid (DMPS), commercially sold as Chemet and Dimaval, respectively. We have used a combination of mercury L-III-edge X-ray absorption spectroscopy and density functional theory calculations to investigate the chemistry of interaction of mercuric ions with each of these chelation therapy drugs. We show that neither DMSA nor DMPS forms a true chelate complex with mercuric ions and that these drugs should be considered suboptimal for their clinical task of binding mercuric ions. We discuss the design criteria for a mercuric specific chelator molecule or custom chelator, which might form the basis for an improved clinical treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available